These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1728 related items for PubMed ID: 16275814

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Effects of methylphenidate on subtypes of attention-deficit/hyperactivity disorder.
    Gorman EB, Klorman R, Thatcher JE, Borgstedt AD.
    J Am Acad Child Adolesc Psychiatry; 2006 Jul; 45(7):808-16. PubMed ID: 16832317
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children.
    Swanson J, Gupta S, Guinta D, Flynn D, Agler D, Lerner M, Williams L, Shoulson I, Wigal S.
    Clin Pharmacol Ther; 1999 Sep; 66(3):295-305. PubMed ID: 10511066
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
    Fallu A, Richard C, Prinzo R, Binder C.
    Curr Med Res Opin; 2006 Dec; 22(12):2557-66. PubMed ID: 17166338
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Buspirone versus methylphenidate in the treatment of children with attention- deficit/ hyperactivity disorder: randomized double-blind study.
    Mohammadi MR, Hafezi P, Galeiha A, Hajiaghaee R, Akhondzadeh S.
    Acta Med Iran; 2012 Dec; 50(11):723-8. PubMed ID: 23292622
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Methylphenidate dosing: twice daily versus three times daily.
    Stein MA, Blondis TA, Schnitzler ER, O'Brien T, Fishkin J, Blackwell B, Szumowski E, Roizen NJ.
    Pediatrics; 1996 Oct; 98(4 Pt 1):748-56. PubMed ID: 8885956
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder.
    Lee SI, Hong SD, Kim SY, Kim EJ, Kim JH, Kim JH, Park MK, Park S, Park JH, Oh EY, Lim TS, Cheong S, Cho IH, Choi JW.
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan 30; 31(1):210-6. PubMed ID: 17046131
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.
    Clin Ther; 2007 Jun 30; 29(6):1168-77. PubMed ID: 17692731
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 87.